**Supplemental Table S4. Post-treatment antineoplastic medication**

|  |  |  |  |
| --- | --- | --- | --- |
| **Antineoplastic Treatmentb,  *n* (%)** | **Spartalizumab  400 mg Q4W (*N* = 82)** | **Chemotherapya (*N* = 40)** | **Crossover to Spartalizumab 400 mg Q4W (*N* = 25)** |
| Chemotherapy | 48 (58.5) | 11 (27.5) | 10 (40) |
| Immunotherapy | 4 (4.9) | 7 (17.5) | 4 (16) |
| Spartalizumab | N/A | 25 (62.5) | NA |
| Other | 3 (6.3) | 3 (7.5) | 2 (8) |
| Unknown | 0 | 1 (2.5) | 0 |
| NA, not applicable; Q4W, every 4 weeks. a Per investigator's choice. b A patient will be counted in each treatment category in the table if they have received multiple antineoplastic therapies. | | | |